Monashee Investment Management LLC purchased a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 120,000 shares of the company’s stock, valued at approximately $1,270,000. Monashee Investment Management LLC owned approximately 0.18% of Kura Oncology as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Nisa Investment Advisors LLC boosted its holdings in Kura Oncology by 147.3% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,325 shares of the company’s stock valued at $28,000 after acquiring an additional 1,385 shares during the period. Point72 Middle East FZE acquired a new stake in Kura Oncology during the 4th quarter worth approximately $115,000. Exchange Traded Concepts LLC purchased a new position in Kura Oncology in the 2nd quarter valued at approximately $118,000. Virtu Financial LLC acquired a new position in shares of Kura Oncology in the second quarter worth $129,000. Finally, Jump Financial LLC purchased a new stake in shares of Kura Oncology during the first quarter worth $146,000.
Kura Oncology Stock Performance
Shares of Kura Oncology stock traded up $0.08 during trading on Monday, reaching $9.64. The company’s stock had a trading volume of 54,833 shares, compared to its average volume of 736,208. The company has a 50-day moving average price of $8.79 and a two-hundred day moving average price of $10.37. Kura Oncology, Inc. has a fifty-two week low of $7.41 and a fifty-two week high of $16.14. The firm has a market cap of $715.98 million, a PE ratio of -4.73 and a beta of 0.65. The company has a current ratio of 16.71, a quick ratio of 16.71 and a debt-to-equity ratio of 0.02.
Wall Street Analyst Weigh In
Kura Oncology Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.
- Five stocks we like better than Kura Oncology
- How to Invest in Blockchain Stocks Step by Step
- Target these 3 hot retail stocks for Black Friday deals
- High Flyers: 3 Natural Gas Stocks for March 2022
- Dell Technologies breaks out, riding high on AI
- How to Invest in Blue Chip Stocks
- Cisco stock plummets on weak forecast: Is it a warning for tech?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.